ClinicalTrials.gov record NCT07611786

Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 17, 2026

Evaluation of a Healthcare Transition Protocol for Patients With Congenital Adrenal Hyperplasia

StatusNot yet recruitingThe study has been registered but has not started enrolling. Sites and contacts may not be listed yet.
Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.
Healthy volunteersAcceptedPeople who do not have the condition being studied who are allowed to take part. Some studies include both people with the condition and healthy volunteers; others may enrol only healthy volunteers.
Age16 years old and older
SexAll
LocationUnited States
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This prospective, single-arm study will deliver and evaluate a structured transition program (CAH-T) for adolescents and young people with congenital adrenal hyperplasia, with one caregiver per participant. The study measures feasibility and acceptability and collects baseline, post-intervention, and 12‑month data on transition readiness, CAH knowledge, emergency preparedness, continuity of endocrine care, and quality of life. Interviews with participants, caregivers, and providers will explore experiences with the program.

What it is studying. The study aims to learn whether the CAH-T program can be delivered as planned in a pediatric clinic, whether patients and caregivers find it acceptable, and to measure preliminary changes in transition readiness, CAH-specific knowledge, emergency preparedness, linkage to adult endocrinology care, and health-related quality of life.

What the researchers hope to learn. Evaluate feasibility and acceptability of a CAH-specific transition program; estimate preliminary changes in transition readiness, CAH knowledge, emergency preparedness, continuity of adult endocrine care, and quality-of-life measures to inform refinement and future multi-site trials.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

The purpose of this study is to implement and evaluate the feasibility and acceptability of a structured healthcare transition program for adolescents and young adults with congenital adrenal hyperplasia (CAH). The study will also examine preliminary effects of the program on transition readiness, disease-specific self-management knowledge, emergency preparedness, continuity of endocrine care, and health-related quality of life as participants transition from pediatric to adult healthcare services.

Interventions being studied

Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.

Other
  • exposure to healthcare transition protocol

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

  • YA Participants
  • Diagnosis of congenital adrenal hyperplasia (any subtype or severity)
  • Age ≥16 years
  • Active follow-up within the pediatric endocrinology clinic
  • English-speaking
  • Cognitively able to complete questionnaires with or without assistance
  • Anticipated ability to participate in CAH-T visits during the study period Caregiver Participants
  • Parent, guardian, or primary support person of an enrolled AYA participant Provider Participants
  • Pediatric endocrinologists, nurse practitioners, or transition-related clinical staff involved in CAH care for at least 6 months

Exclusion criteria

  • Significant cognitive impairment precluding participation
  • Inability to complete study procedures
  • Inability to provide informed consent/assent

Study description and what participation involves

The study's detailed description, as published on ClinicalTrials.gov.

Show the detailed description from the registry

Study Purpose and Rationale Congenital adrenal hyperplasia (CAH) is a complex, lifelong endocrine disorder that requires continuous glucocorticoid replacement, stress-dosing during illness, and ongoing monitoring for metabolic, reproductive, and adrenal complications. Adolescents and young adults face substantial challenges maintaining these self-management responsibilities during the transition from pediatric to adult care, a period consistently associated with decreased adherence, reduced clinic attendance, lapses in emergency preparedness, and preventable adrenal crises. Despite these risks, there are currently no structured, evidence-informed transition programs tailored specifically to the needs of individuals with CAH. The purpose of this study is to evaluate the feasibility, acceptability, and preliminary impact of implementing the Comprehensive Adolescent Healthcare Transition (CAH-T) program for adolescents and young adults with CAH. By combining structured education, readiness assessment, emergency preparedness training, and coordinated transfer to adult endocrinology, this mixed-methods pilot aims to strengthen self-management skills, improve continuity of care, and reduce acute health events. Findings will inform refinement of the CAH-T model and provide essential pilot data needed to support future multi-site implementation. Objectives and Hypotheses The overall objective of this mixed-methods feasibility study is to evaluate the implementation and preliminary effectiveness of the Comprehensive Adolescent Healthcare Transition (CAH-T) program for adolescents and young adults with congenital adrenal hyperplasia (CAH). The study aims to determine whether the intervention can be feasibly delivered in a pediatric endocrine clinic, is acceptable to patients and caregivers, and produces early improvements in transition-related outcomes. The investigators hypothesize that.

  • The CAH-T program will be feasible to implement, with recruitment, retention, and curriculum completion meeting predefined benchmarks.
  • Participants and caregivers will rate the program as satisfactory.
  • Participation in CAH-T will lead to improvements in transition readiness, CAH-specific knowledge, emergency preparedness, and successful linkage to adult endocrinology care, while supporting stable health-related quality of life.

Study Design Overview This is a prospective, single-center, single-arm, mixed-methods feasibility and implementation study conducted over 24 months. Adolescents and young adults aged 16-20 years with a diagnosis of CAH, along with one of their caregivers, will participate in a structured transition curriculum integrated into routine endocrine visits. Quantitative measures of readiness, knowledge, quality of life, and emergency preparedness will be collected at baseline, post-intervention, and at 12-month follow-up. Semi-structured interviews with adolescents, caregivers, and providers will be used to contextualize quantitative findings and identify implementation barriers and facilitators. Population and Sample Size Summary The study will enroll approximately 15 adolescents and young adults with CAH (ages 16 years and older) and one caregiver per participant from the Children's Hospital of Alabama pediatric endocrinology clinic. This sample size is appropriate for feasibility pilot work in a rare disease population and will provide sufficient data to estimate feasibility metrics, evaluate acceptability, and generate preliminary effect-size estimates for future multi-site trials. Primary and Secondary Outcomes Primary Outcomes

  • Feasibility:
  • Recruitment ≥75% of eligible participants within the 24 months of the study timeline
  • Retention ≥80% at 6- and 12-month follow-up
  • Curriculum completion ≥70% for participants enrolled by their 12-month follow-up endpoint.
  • Acceptability: ≥80% of participants and caregivers rate the program "satisfied/very satisfied" at their 12-month follow-up

Secondary Outcomes

  • Transition Readiness: ≥10% improvement in STARx/STARx-P scores at the 12 month follow-up compared to a baseline score.
  • CAH-Specific Knowledge: ≥10% improvement in CAHKAQ scores at the 12 month follow-up compared to a baseline score.
  • Emergency Preparedness:
  • ≥70% medical alert use
  • ≥90% possession of injectable hydrocortisone
  • ≥80% updated adrenal insufficiency action plan in the chart
  • Health-Related Quality of Life: ≤10% change in CAHQL scores over 12 months
  • Transfer Outcomes: ≥80% of eligible participants attend at least one adult endocrinology visit within 6 months post-transfer
  • Acute Care Utilization: Stable or reduced emergency/urgent care visits pre- vs. post-intervention

Brief Procedures Summary Participants will complete a baseline assessment including demographics, CAH knowledge (CAHKAQ),9 transition readiness (STARx/STARx-P),10-12 emergency preparedness, and quality-of-life measures (CAHQL).13 They will then participate in two CAH-T curriculum14 visits embedded in routine endocrine appointments. Age-eligible participants (over 18 years old) will be transferred to adult care following completion of the curriculum and monitored for completion of an adult endocrinology visit. All participants will complete a 12-month follow-up assessment, and emergency care utilization will be recorded for the year preceding enrollment and for the year following intervention completion. Semi-structured interviews will be conducted with adolescents, caregivers, and providers after the program's implementation to explore perceptions of the program's feasibility and acceptability. Significance / expected impact This study aims to address a significant gap in endocrine transitional care by piloting the first structured, CAH-specific transition program at a U.S. pediatric center. The implementation of CAH-T is expected to improve self-management skills, enhance preparedness for adrenal crises, support a stable quality of life, and increase successful connection to adult endocrinology care. Findings will generate foundational evidence needed to refine the intervention and support future multi-site trials aimed at establishing best practices for transition in rare endocrine disorders.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Participants complete baseline questionnaires about CAH knowledge, transition readiness, emergency preparedness, and quality of life. They take part in two CAH-T curriculum visits (about 3 and 6 months after enrollment) during routine endocrine appointments, including education, emergency injection teach-back, and transfer planning for those ≥18. All participants complete a 12-month follow-up assessment and researchers will record emergency/acute care use for the year before and the year after the intervention. After the program, some participants, caregivers, and providers will be interviewed about their experience.

How the study is structured. A prospective, single-center, single-arm mixed-methods feasibility study over 24 months. Enrolled adolescents and young adults will complete baseline assessments, attend two CAH-T curriculum visits (about 3 and 6 months after enrollment), and complete a 12-month follow-up assessment. Researchers will collect questionnaires at baseline, 6 months, and 12 months and conduct semi-structured interviews with patients, caregivers, and providers to understand implementation and experience.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

  • This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
  • The registry says recruitment has not started. When is it expected to open, and can I register interest now?
  • The listed sites are in United States. Is any of them reachable for me, and does the study help with travel?
  • Which of the eligibility criteria would need to be checked with tests before I could join?

More on congenital adrenal hyperplasia

Important dates

Study start
October 2026 (estimated)
Primary completion
October 2028 (estimated)
Study completion
October 2029 (estimated)
Target enrollment
40 participants (estimated)
Last updated on registry
Aug 21, 2026
Data verified
Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor
University of Alabama at Birmingham
Principal investigator
Christy Foster, primary investigator
University of Alabama at Birmingham
Collaborators
  • Neurocrine Biosciences

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Participating sites (1)

Terms used on this page · explanations by MedicalUpdates.ai

follow-up
The period after treatment or enrolment during which participants are observed or contacted, for example to record side effects or outcomes.
informed consent
The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
assent
A child's or dependent adult's agreement to take part, given alongside the formal consent of a parent or legal representative.
Inclusion Criteria
The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria
The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
glucocorticoid
Steroid medicines, such as prednisone, that reduce inflammation. Studies often require a stable dose at entry or measure whether the study treatment allows the dose to be reduced.
single-arm
All participants receive the same treatment or follow the same plan. There is no comparison group within the study.
baseline
Measurements taken at the start of the study, before any study treatment, so that later results can be compared with them.
endpoint
Something the study measures to judge its results, such as a symptom score, a blood test or survival. Outcomes are grouped as primary, secondary and sometimes exploratory.
enrollment
The number of participants a study plans to include, or has included. 'Estimated' means the planned number; 'actual' means the number who joined.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials